RecruitingRecruiting
Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)
NCT07375992 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM) J2556
About this study
Virtually via Zoom, all participants will meet with Music Therapists to create playlists and learn how to complete surveys measuring quality of life.
Participants will be randomly assigned, half to each arm. Arm A will interact with Music Therapists and listen to music twice a week, then independently fill out quality of life questionnaires.
Arm B will listen to music independently twice a week, then independently fill out quality of life questionnaires.
Eligibility criteria
Inclusion Criteria:
* Glioblastoma (Newly Diagnosed)
* Cognitive capacity to respond to surveys
* Access to computer and web access
* Ability to attend virtual music therapy sessions
* Audibly process music
* Proficient in English
Exclusion Criteria:
* Not planning to undergo standard of care radiation therapy and concurrent and adjuvant temozolomide.
* A life expectancy of less than 6 months.
* Concurrent use of any other standard or investigational agents (excepting tumor treating fields).
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit adherence with study requirements.
Study design
Enrollment target: 35 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-05-26
Estimated completion: 2029-02-28
Last updated: 2026-06-18
Interventions
Other: Music intervention
Primary outcomes
- • Success rate of Music Therapy intervention for GBM patients (6 months)
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · other
With: Keep Punching Foundation
Contacts & investigators
ContactPrincipal Investigator- Matthias Holdhoff, MD, PhD. · contact · bcp-iis@jh.edu · 410-995-8837
InvestigatorMatthias Holdhoff, MD, PhD. · principal_investigator, Johns Hopkins -Sidney Kimmel Cancer Center
InvestigatorGrace Tobin, MD · principal_investigator, Johns Hopkins University
All locations (1)
Oncology- BroadwayRecruiting
Baltimore, Maryland, United States